ArticleJournal of neuro-oncology2026
[
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeAmong oligodendrogliomas, World Health Organization (WHO) grade 2 tumors have relatively more favorable prognosis compared to the grade 3. However, heterogeneity in tumoral behavior exists in grade 2 oligodendrogliomas, with some exhibiting an aggressive course. The authors applied [18F]FET-PET in oligodendrogliomas and extended its utility in predicting prognosis of low-grade oligodendrogliomas.
methodsTwelve consecutive patients with oligodendrogliomas treated at our institution (Oligo-WHO2: n = 8; Oligo-WHO3: n = 4) were enrolled. All patients underwent contrast-enhanced MRI and [18F]FET-PET/MR before surgery. Maximum and mean target-to-background ratios (TBRmax, TBRmean) were evaluated, and progression-free survival (PFS) was recorded. Bulk RNA sequencing and immunohistochemical(IHC) staining were performed for the verification of [18F]FET-PET findings.
resultsAll grade-3 oligodendrogliomas presented high [18F]FET uptake on PET and contrast-enhancement on MRI. Although all grade-2 tumors were non-enhanced, only 50% showed low uptake of [18F]FET, which thus dissected grade-2 oligodendrogliomas into two subgroups: Oligo-WHO2-Low-Uptake and Oligo-WHO2-High-Uptake tumors. Using cutoff of TBRmax = 2.5, [18F]FET-PET based stratification was more correlated with PFS, compared to the WHO grade classification, with all of 4 recurrent oligodendrogliomas (2/4 were grade-2) being [18F]FET high-uptake. Transcriptional results revealed clear discrimination: Oligo-WHO2-High-Uptake tumors were enriched with pathways of energy metabolism and tumor chemotaxis, while the Oligo-WHO2-High-Uptake group displayed upregulation of myelin formation-related pathways. Representative protein markers were selected for validation, with IHC staining unveiling AK4, CXCL5, and IL-33 highly expressed in Oligo-WHO2-High-Uptake oligodendrogliomas and SOX10 enriched in Oligo-WHO2-Low-Uptake tumors.
conclusionWHO grade 2 oligodendrogliomas is a heterogeneous composition of tumors with distinct prognosis and molecular characteristics. [18F]FET-PET represents a promising radiological tool for dissecting these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.